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ABSTRACT
We prospectively compared outcomes after a fludarabine (Flu) plus oral busulfan (Bu)–containing reduced-
intensity conditioning regimen (150 mg/m2 Flu and 10 mg/kg oral Bu), with (n  32; Flu-TBu group) or
without (n  30; Flu-Bu group) therapeutic dose monitoring and dose adjustment of Bu. All patients received
peripheral blood stem cells from a genoidentical sibling, and study cohorts had similar patient characteristics.
Dose adjustments of Bu were required in 20 (63%) patients in the Flu-TBu group (median final dose,
8.89 mg/kg; range, 6.3-13.34 mg/kg). Donor T-cell and granulocyte engraftments were similar, and early
conditioning-related toxicities were mild and similar in both study groups. With a median follow-up of 45 months
(51 months in the 37 survivors), posttransplantation outcomes did not differ between cohorts. The strongest
predictor of 2-year overall survival and leukemia-free survival was the presence of chronic graft-versus-host disease
(77% versus 34% for overall survival and 74% versus 34% for leukemia-free survival; P< .001 for both outcomes).
In conclusion, therapeutic dose monitoring of oral Bu in a reduced-intensity conditioning setting does not seem to
affect outcome, although further studies may identify very-high-risk patients who benefit from this strategy.
© 2005 American Society for Blood and Marrow Transplantation
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HNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) is a potentially curative treatment for
atients with myeloid malignancies, including high-
isk myelodysplastic syndromes (MDS) and acute my-
logenous leukemia (AML). Conventional myeloabla-
ive conditioning regimens for patients with myeloid
alignancies have consisted of the combination of
yclophosphamide (Cy) and whole-body irradiation or
ral busulfan (Bu) [1-5]. A serious limitation of these
egimens is the associated toxicity that requires in-
ense supportive care and predisposes debilitated and p
B & M Tlderly patients to a high risk of nonrelapse mortality
NRM) from direct organ toxicity, infections, and
raft-versus-host disease (GVHD) [5,6]. Oral Bu has
n unpredictable intestinal absorption, and a well-
nown handicap of this formulation is the consider-
ble interpatient and intrapatient variations in bio-
vailability and drug exposure [7,8]. The systemic
xposure to Bu (reported as area under the concentra-
ion-versus-time curve [AUC] or average concentra-
ions at steady state [Css]) affects the outcome of pa-
ients conditioned with Cy plus high-dose Bu (BuCy).
igher organ toxicities (especially hepatic) occur in
atients exposed to high levels of Bu, [9-11] whereas
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4ower exposures lead to a higher incidence of relapse
12]. Therefore, therapeutic drug monitoring (TDM)
as been proposed to maximize the likelihood of
chieving exposures to Bu within a desired therapeutic
indow, with very good results in patients with my-
loid malignancies [13,14].
All these data refer to standard myeloablative
uCy conditioning. Recently, data of less toxic my-
loablative regimens have been developed by substi-
uting Cy for ﬂudarabine (Flu) combined with Bu with
DM given at myeloablative doses (16 mg/kg orally)
ver 4 days (orally 4 times daily as in the traditional
uCy regimen [15] or as a single daily intravenous
nfusion [16,17]), with very low incidences of NRM in
oth related and unrelated donor transplantations.
owever, these Flu plus high-dose Bu (for 4 days)
rotocols have been applied to patients at standard
isk for NRM and were not designed as reduced-
ntensity conditioning (RIC) regimens for patients at
igh risk for NRM.
In recent years, numerous RIC regimens have
een developed with the aim of reducing NRM in
igh-risk patients while allowing sustained engraft-
ent of allogeneic hematopoietic stem cells, not only
rom matched related, but also from unrelated, donors
18-35]. The ﬁrst Flu-Bu RIC regimen was initially
esigned and reported by Slavin et al., [26] who used
lu (180 mg/m2) combined with low-dose
8 mg/kg) oral Bu and antithymocyte globulin. Later
eports showed that antithymocyte globulin was not
ssential for achieving stable engraftment of periph-
ral blood stem cells (PBSCs) from matched related
onors after conditioning with Flu 150 mg/m2 and Bu
-10 mg/kg[36-38]. Because RIC regimens are de-
igned to minimize organ toxicities and NRM while
btaining sustained donor-derived chimerism, TDM
f Bu in such protocols may further improve the
olerability of Bu-based RIC, but this possibility has
ot been studied.
The aim of this prospective study was to analyze
hether a combination of Flu 150 mg/m2 and re-
uced-dose oral Bu (10 mg/kg) over 2.5 days with or
ithout dose adjustments to target exposure of Css 800
o 1000 ng/mL would modify the engraftment and
ransplantation outcomes after allogeneic HSCT of
BSC from HLA-compatible siblings in patients with
yeloid malignancies. The steady-state targeted
lasma level was chosen on the basis of previous stud-
es with BuCy, [13,14,39,40] even though an oral dose
f 16 mg/kg was used in all prior studies.
ATIENTS AND METHODS
atient Eligibility and Accrual
All 62 patients included in this prospective study
eceived an allogeneic PBSC transplant from an HLA w
38dentical sibling within a multicenter study [20] be-
ween January 1999 and December 2003. The proto-
ol was designed only for patients with poor-risk my-
loid malignancies who had a contraindication for a
tandard myeloablative HSCT (details described be-
ow). For inclusion, patients with myeloid malignan-
ies had to have high-risk AML or MDS (an interme-
iate-2 or high International Prognostic Score [41]),
ccording to standard recommendations [42].
The ethics committees and local regulatory agen-
ies approved the protocol, and all patients signed
nformed consent. In an effort to analyze the effect of
DM of Bu in such an RIC strategy, 32 consecutive
atients with AML, MDS, or chronic myelogenous
eukemia (CML) allografted at the Hospital de la
anta Creu i Sant Pau (Barcelona, Spain) underwent
DM of Bu with dose adjustment (Flu-TBu group),
nd 30 consecutive patients who underwent transplan-
ation during the same period in Salamanca (Spain)
eceived the total dose of Bu without TDM (Flu-Bu
roup). Although the study was not randomized,
oth centers have completely different areas of pa-
ient referral, and the conditioning protocol, sup-
ortive care, methods, and timing of posttransplan-
ation disease monitoring were identical except for
he targeted Bu used in the Flu-TBu group. All
atients treated were analyzed, and patient and dis-
ase characteristics were similar in both groups (de-
ailed in Table 1), thus conﬁrming the lack of a
atient selection bias. During the study period, no
atient with myeloid leukemia who met the inclu-
ion criteria in either center received an alternative
ransplantation protocol. Patient details are shown
n Table 1. The source of stem cells was peripheral
lood in all cases, and all donors were genotypically
dentical siblings. Of note is the high proportion of
atients with poor-risk or very-poor-risk cytogenet-
cs in both groups, as deﬁned by established criteria
n AML [43] and MDS [41].
The reasons for inclusion in an RIC protocol
nd exclusion from (or contraindications to) stan-
ard conditioning in each transplantation group
ere also similar. Thirty-ﬁve percent of patients
ad more than 1 contraindication, and the most
ommon were age 50 years (75% versus 79% in
he Flu-TBu and Flu-Bu group, respectively) and
oor cardiac function (left ventricular ejection frac-
ion 40% of expected value or symptomatic car-
iac disease) or poor pulmonary function (diffusing
apacity of the lung for carbon monoxide 40% of
xpected value), which occurred in 20% versus
2%, respectively. Other contraindications are
hown in Table 1. Preliminary results of 19 patients
ncluded in a previous report [36] are included here
ith an extended follow-up of more than 2 years.
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Fludarabine and Targeted Busulfan as Conditioning Therapy
Bonditioning Regimens and GVHD Prophylaxis
All patients were conditioned with Flu (30 mg/m2
ntravenously from days 9 to 5) and oral Bu (10
able 1. Patient Characteristics
Variable
ex (M/F)
edian age, y (range)
ge >60 y
atient male/donor female
MV risk group
Patient /donor / (high risk)
Patient /donor  (intermediate risk)
Patient /donor  (low risk)
nderlying disease
Chronic myelogenous leukemia
Other chronic myeloproliferative syndromes
AML
MDS
RA/RAEB/other
Chronic myelomonocytic leukemia
PSS score (in MDS)
Low/int-1
Int-2/high
rigin of AML/MDS
De novo AML/MDS
Secondary (post-MDS) AML
Therapy-related AML/MDS
onths from diagnosis, median (range)
ytogenetic risk group in AML*/MDS†
Not available
Good/intermediate
Poor/very poor
Prior autologous HSCT‡
isease phase at transplantation§
Early
Nonearly
5% / >10% BM blasts at transplantation
lasts in PB at transplantation
ML-type chemotherapy before transplantation
ytogenetic abnormalities at transplantation
oor ECOG PS (2/3)
omorbidity score#
0
1-2
>3
CD34 cells ( 106/kg), median (range)
MV indicates cytomegalovirus; M/F, male/female; AML, acute my
MDS, myelodysplastic syndromes; IPSS, International Prognos
Oncology Group performance status; PB, peripheral blood; HS
one of the baseline patient characteristics differed between group
ata are n (%) unless otherwise noted.
Classiﬁed according to the European Organization for Resear
dell’Adulto. [43]
Classiﬁed according to the IPSS criteria. [41]
Five patients had received an autologous transplant for a lymphoid
relapsed after transplantation for AMI.
Disease phase at transplantation was deﬁned as early phase (treated
in ﬁrst complete remission, untreated MDS with 5% blasts in
excess blasts in bone marrow at transplantation, or CML in ﬁrs
“AML-type chemotherapy” refers to remission-induction therapy
or without other drugs.
Comorbidity score calculated as described elsewhere. [6]g/kg total dose, given at 1 mg/kg every 6 hours on p
B & M Tays 4 to 2). The dose was calculated on the basis
f the adjusted body weight. In the Flu-TBu group, Bu
ose adjustments were made as described below. For
geted Busulfan Patients Nontargeted Patients
32 30
20/12 20/10
56 (35-66) 59 (22-69)
10 (31) 12 (40)
9 (28) 8 (27)
27 (85) 26 (87)
3 (9) 3 (10)
2 (6) 1 (3)
5 (16) 4 (13)
1 1
16 (50) 15 (50)
10 (38) 10 (40)
0/4/3 3/3/2
3 2
0/3 0/3
5/2 3/4
14 (54) 15 (60)
4 (15) 4 (16)
8 (31) 6 (24)
8 (2-84) 8 (1-77)
0 2 (8)
1 (4)/6 (22) 0/10 (40)
12 (44)/8 (30) 7 (28)/6 (24)
5 (16) 4 (13)
16 (50) 16 (53)
16 (50) 14 (47)
9 (28)/6 (19) 8 (27)/5 (17)
9 (28) 5 (17)
18 (56) 18 (60)
18 (56) 10 (33)
6 (19) 4 (13)
12 (38) 14 (47)
17 (53) 12 (40)
3 (9) 4 (13)
7.9 (2.6-15.6) 6.3 (2-10)
ous leukemia; RA, refractory anemia; RAEB, RA with excess blasts;
ring System; BM, bone marrow; ECOG PS, Eastern Cooperative
matopoietic stem cell transplantation; int, intermediate.
Treatment of Cancer/Gruppo Italiano Malattie Ematologiche
ancy and developed therapy-related AML or MDS, whereas 4 had
and MDS with 5% blasts in bone marrow at diagnosis and were
arrow at transplantation) (refractory anemia, other MDS without
ic phase) or nonearly phase (other disease status).
anthracycline for 3 days plus cytosine arabinoside for 7 days, withTar
elogen
tic Sco
CT, he
s.
ch and
malign
AML
bone m
t chron
with anrevention of seizures, all patients received oral phe-
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4ytoin before and during Bu administration, and gran-
locyte colony-stimulating factor was not given after
ransplantation in either group.
Prophylaxis for acute GVHD (aGVHD) consisted
f cyclosporine from day 7, plus a short course of
ethotrexate (10 mg/m2 intravenously on days 1,
3, and 6), followed by folinic acid. Cyclosporine
apering began on day 90 if GVHD and disease
ecurrence did not develop earlier [20,36]. Donor
ymphocyte infusions (DLIs) were planned in both
enters in case of disease progression (preceded by
ML-type chemotherapy if necessary) if GVHD was
ot present, as well as in case of persistent mixed
onor-recipient chimerism after cyclosporine with-
rawal with evidence of persisting or increasing min-
mal residual disease (MRD; no prior chemotherapy).
cute GVHD and chronic GVHD (cGVHD) were
iagnosed and graded by using established criteria
44,45]. Acute GVHD and cGVHD were treated with
rednisone, cyclosporine, or mycophenolate mofetil.
ngraftment, Quantitative Donor Chimerism,
nd MRD
Donor cell engraftment was assessed in both
roups in peripheral blood nucleated cells by quanti-
ative polymerase chain reaction of variable numbers
f tandem repeat after transplantation, as previously
escribed in detail [37,46]. T cells and granulocytes
ere separated for subset chimerism in most cases,
nd unfractionated nucleated cells were also tested.
omplete donor chimerism (CDC) was deﬁned as
00% donor cells (sensitivity of 1% in both centers),
hereas mixed chimerism indicated the presence of
1% recipient cells in the sample analyzed.
In patients with CML, quantitative real-time poly-
erase chain reaction for the bcr/abl gene was per-
ormed in all cases by using a standardized technique
47] at regular intervals after transplantation to mon-
tor MRD. Before transplantation, all patients with
ML had an abnormal karyotype. Of the 51 patients
ith AML/MDS, 34 had an abnormal karyotype at
iagnosis, and at transplantation 19 of 27 patients with
n informative karyotype (20 metaphases analyzed)
till had detectable cytogenetic abnormalities in bone
arrow, with no differences between groups.
usulfan Pharmacokinetic Analysis and
osage Adjustment
In the Flu-TBu group, for the pharmacokinetic
haracterization of an individual patient, a 1-compart-
ent absorption model was ﬁtted to the available
oncentration-time values by weighted nonlinear re-
ression, and the elimination rate constant, volume of
istribution, and absorption rate constant were esti-
ated [39]. The apparent oral clearance, AUC, andverage Css were calculated. Estimation was per- u
40ormed by using the ADAPT-PC collection (Univer-
ity of Southern California Los Angeles). To provide
ccurate assessments of Bu exposure during condition-
ng, blood samples were collected at 0 hours (just
efore the dose) and at 1, 2, 4, and 6 hours after the
rst dose of Bu on day 1. The Bu Css is the ratio of Bu
UC over the dosing interval between doses (6
ours). If the Css achieved was less than 800 ng/mL or
ore than 1000 ng/mL, subsequent doses were lin-
arly adjusted to achieve the target. Because this was
n RIC regimen, we chose to systematically resample
n both days 2 and 3 only in patients for whom the
ose was changed by more than 20% of the prior dose.
owever, to check the accuracy of the dose selected,
harmacokinetic analyses were repeated after the ﬁfth
n 27) and/or the ninth (n 20 patients) doses (ﬁrst
ose on days 2 and 3 of Bu, respectively) in all patients.
egimen-Related Toxicity
Regimen-related toxicity was scored by using the
ommon Toxicity Criteria version 3 (CTCAE 3.0) of
he National Cancer Institute of the United States
http://ctep.cancer.gov/reporting/ctc.html). The co-
orbidity score was determined as previously de-
cribed [6]. Mucosal and hepatic toxicity was com-
ared in detail by registering the need for and
uration of intravenous total parenteral nutrition and
y comparing levels of bilirubin and liver enzymes at
umerous time points during conditioning and after
ransplantation.
upportive Care
Similar infectious disease prophylaxis strategies
ere used during this study in both centers, including
ntibacterial prophylaxis and therapy, antifungal pro-
hylaxis with ﬂuconazole, and acyclovir prophylaxis
uring the ﬁrst 2 weeks after transplantation for her-
es simplex virus prophylaxis [21,48]. Cytomegalovi-
us (CMV) infection was monitored at least weekly
ith pp65 antigenemia, [49] and in case of a positive
est result, preemptive therapy with ganciclovir or
oscarnet was initiated [50].
tatistical Analysis
The major goals of this study were to compare the 2
IC strategies in terms of NRM, overall survival (OS),
nd early posttransplantation toxicities. Secondary end
oints included T-cell and granulocyte engraftment, re-
apse incidence, and aGVHD and cGVHD.
Patient characteristics were compared among
reatment groups by the 2 test or Fisher exact test for
ategorical variables and by the t test or Wilcoxon test
or variables measured on a continuous scale. The
robabilities of OS and leukemia-free survival (LFS)
ere estimated from the time of transplantation by
sing the Kaplan-Meier product-limit estimate with
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Fludarabine and Targeted Busulfan as Conditioning Therapy
Btandard methods [51,52]. The 2-sided log-rank test
as used to test the univariate association between
ariables and OS and LFS. The incidences of NRM,
isease relapse or progression, aGVHD and cGVHD,
MV infection, and achievement of CDC (in each cell
ubset analyzed) were calculated by using cumulative
ncidence estimates and taking into account the com-
eting risks. Univariate analyses of NRM and disease
elapse were performed with univariate Cox regres-
ion models. Acute GVHD and cGVHD, CMV in-
ection, and achievement of CDC were evaluated as
ime-dependent covariates. Multivariate analyses were
erformed with Cox proportional hazards regression,
ith inclusion of variables with a P value .10 in the
rior univariate testing. Variables analyzed for trans-
lantation outcomes were transplantation group, dis-
ase group (AML/MDS versus CML), origin of
ML/MDS (de novo versus therapy-related AML/
DS versus secondary AML), age (as a continuous
ariable and as 60 versus 60 years), patient sex, sex
ismatch (female donor to male recipient versus
ther), time from diagnosis to transplantation (as a
ontinuous variable), disease phase (early versus non-
arly), cytogenetic risk group in AML/MDS (interme-
iate versus poor or very poor), percentage of bone
arrow blasts at transplantation (10% versus 10),
resence of blasts in the peripheral blood at transplan-
ation, prior autologous transplantation, patient CMV
erostatus, Eastern Cooperative Oncology Group per-
ormance status (0/1 versus 2/3), comorbidity index (0
ersus 1/2 versus 3), International Prognostic Score
n MDS (low/intermediate-1 versus intermediate-2/
igh), occurrence of grade II to IV aGVHD, and
ccurrence of cGVHD. Additionally, the effect of the
D34 cell dose (as a continuous variable and as 6
106/kg versus 6  106/kg) was adjusted for pos-
ible intercenter variability, as reported previously in
etail [53]. Transplantation group (Flu-TBu versus
lu-Bu) was kept in all multivariate analyses even
hough it may not have been statistically signiﬁcant in
nivariate analysis, because it was our aim to estimate
he effect of TDM and dose adjustment of Bu on all
utcomes while adjusting for the other potential prog-
ostic factors. The assumption of proportional haz-
rds over time was tested for all explanatory covariates
y using a time-dependent covariate.
ESULTS
usulfan Levels and Targeting
Busulfan Css levels were measured for all patients
n the Flu-TBu group. On day 1, the median Bu Css
evel was 1058 ng/mL (range, 463-1958 ng/mL); 12
atients (38%) had values in the prescribed target
ange of 800 to 1000 ng/mL. Eighteen patients re-
uired Bu dose reductions, and 2 required increases. m
B & M Tn day 3, the median Bu Css level was 822 ng/mL
range, 643-1183 ng/mL), and 14 (70%) of 20 patients
ad levels in the target range. The median total dose
f Bu administered in all 10 doses to all 32 patients
as 8.98 mg/kg (range, 6.3-13.34 mg/kg). The medi-
ns and ranges for doses of Bu and pharmacokinetic
ata on days 1, 2, and 3; the target levels achieved each
ay; and the dose adjustments according to prior Css
nd AUC are shown in Table 2.
ngraftment and Chimerism
All 62 patients achieved sustained engraftment, as
etailed in Table 3. Chimerism tests showed early
eplacement by donor hematopoiesis in all patients,
ith neither early nor late graft failures. Subset chi-
erism analyses (tested in 53 patients) showed that
DC in granulocytes was achieved in 96% of patients
ested, at a median of 29 days after transplantation,
hereas T-cell CDC was achieved in 89% of patients,
t a median of 93 days after transplantation (P  .01
or the kinetics of CDC in T cells versus granulo-
ytes), without differences between transplantation
roups (Figure 1). The proportion of patients who
chieved CDC in T cells before day 45 (30%),
etween day 46 and day 100 (30%), and beyond
ay 100 (28%) did not differ between groups. Of
ote, 3 patients (6%) achieved CDC in T lymphocytes
eyond day 180.
egimen-Related Toxicity and NRM
Transient increases of bilirubin and liver en-
ymes (aspartate aminotransferase, alanine amino-
ransferase, alkaline phosphatase, and -glutamyl-
ranspeptidase) were a common ﬁnding, without
ifferences between groups (Table 3). Reversible
rade 3 and 4 increases of transaminases and bili-
ubin occurred in only 9% and 6% of the cases,
espectively. Only in 1 case (3%) in the nontargeted
roup could a clinical diagnosis of moderate hepatic
eno-occlusive disease be ascertained. Grade 3 to 4
ucositis occurred equally in both groups, whereas
he use and duration of total parenteral nutrition
ere slightly higher in the Flu-Bu (unmonitored)
roup. Grade 3 to 4 diarrhea and abdominal pain
ccurred in 5% of patients in both groups. There
ere no other moderate to severe toxicities. Pa-
ients were discharged from the hospital at a median
f 17 days (range, 10-26 days) after transplantation
n both centers, although the duration of intensive
npatient supportive care and the requirement for
ntravenous medications and hyperhydration lasted
nly a median of 6 days, as previously reported in
etail [54].
The median follow-ups for all patients and for
urvivors as of December 1, 2004, were 42 and 44
onths, respectively, in the Flu-TBu group and 43
441
a
B
l
f
7
(
d
d
1
a
u
n
m
v
(
C
v
a
a
s
d
d
.
1
t
S
n
c
t
T
g
3
3
c
6
7
m
G
c
4
u
o
m
m
.
G
N
T
S
D
D
D
T
D
P
R. Martino et al.
4nd 54 months, respectively, in the Flu-Bu group.
ecause most patients in both groups had a fol-
ow-up 24 months, statistical analyses were per-
ormed at this time point. NRM occurred in 5 and
patients, respectively, at a median of 99 days
range, 76-473 days) and 189 days (range, 69-471
ays) after transplantation, respectively. The 100-
ay and 2-year incidences of NRM were 5% and
2%, respectively, in the Flu-TBu group and 3%
nd 19%, respectively, in the Flu-Bu group. In
nivariate analysis, the variables that showed a sig-
iﬁcant effect on the 2-year NRM were sex mis-
atch (29% for female donor and male recipient
ersus 10% for others; P  .02), CMV infection
58% versus 11% for no CMV infection; P  .04),
D34 cell dose infused (26% for 6  106/kg
ersus 4% for 6  106/kg), and grade II to IV
GVHD (45% versus 10%; P  .01). In multivariate
nalysis, the variables that inﬂuenced NRM were
ex mismatch (hazard ratio [HR], 10.2; 95% conﬁ-
ence interval [CI], 1.7-63; P  .01), CD34 cell
ose 6  106/kg (HR, 14.2; 95% CI, 1.9-154; P 
03), and grade II to IV aGVHD (HR, 8.6; 95% CI,
.9-41; P  .006). Figure 2 shows the NRM by
able 2. Busulfan Pharmacokinetic Parameters (Area under the Curve
teady-State Plasma Levels in the 32 Patients from the Targeted Busulf
Variable
Busulfan Do
(mg/kg)
ay 1
Dose 1 (all patients monitored) 1
Within target range (Css 800-1000)
Below target range (Css <800)
Above target range (Css >1000)
Dose 2 to 4 (adjusted after dose 1) 0.83 (0.66-1.
ay 2
Dose 5 (27 patients monitored) 0.83 (0.66-1.
Within target range (Css 800-1000)
Below target range (Css <800)
Above target range (Css >1000)
Dose 6 to 8 0.85 (0.48-1.
ay 3
Dose 9 (20 patients monitored) 0.85 (0.48-1.
Within target range (Css 800-1000)
Below target range (Css <800)
Above target range (Css >1000)
Dose 10 0.88 (0.7-1.1
otal dose (all 10 doses) 8.98 (6.3-13.
<8 mg/kg 7.9 (6.3-8
(n  6 patient
8.1-10 mg/kg 8.7 (8.03-9.7
(n  12 patien
>10 mg/kg 10 (10-13.7
(n  14 patien
ata are median (range) unless otherwise noted.
indicates predicted Css based on prior pharmacokinetic-based
concentration at steady state.ransplantation group. i
42pontaneous GVHD
The incidence and onset of spontaneous (that is,
ot induced by DLI or abrupt discontinuation of cy-
losporine) aGVHD and cGVHD were similar be-
ween groups (data are shown in detail in Table 3).
he 100-day cumulative incidence of spontaneous
rades II to IV aGVHD was 20% (95% CI, 13%-
2%) in the Flu-TBu group and 22% (95% CI, 14%-
3%) in the Flu-Bu group (P  .70). The 2-year
umulative incidence of spontaneous cGVHD was
5% (95% CI, 49%-74%) and 61% (95% CI, 42%-
0%), respectively (P  .50), whereas the 2-year cu-
ulative incidence of spontaneous moderate to severe
VHD (deﬁned as grades II to IV aGVHD, extensive
GVHD, or both) was 45% (95% CI, 27%-63%) and
9% (95% CI, 29%-69%), respectively (P  .09). In
nivariate analysis, the only risk factor for the devel-
pment of moderate to severe GVHD was sex mis-
atch (2-year incidence: 75% in female donor and
ale recipient versus 35% in other combinations; P
04). Mortality in patients with moderate to severe
VHD was 16 of 33 (3 from relapse and 13 from
RM) and 15 of 29 (14 from relapse and 1 from
the First Oral Dose of 1 mg/kg, Adjusted Busulfan Doses Given, and
up
AUC (ng/h/mL) CSS (ng/mL)
6815.8 (3865-10370) 1058.3 (463-1958.3)
12 (38%); dose unchanged
2 (6%); dose increased
18 (56%); dose decreased
— —
4893.3 (4400-5595) 895.8 (733.3-932.5)
27 (87%); dose unchanged
2 (6%); dose increased
2 (6%); dose decreased
— —
4935.9 (3858-7100) P: 859.9 (671.4-1370.7)
O: 822.7 (643-1183.3)
% deviation: 4.3%
14 (70%); dose unchanged
3 (15%); dose increased
3 (15%); dose decreased
P: 922 (536-1348)
)
)
djustments; O, observed Css; AUC, area under the curve; Css,) after
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BVHD. These results reinforce the link between se-
ere GVHD and NRM.
isease Response
The complete remission (CR) rate on day28 was
8% among 17 patients with AML/MDS undergoing
able 3. Transplantation outcome
Variable
ay to 0.5  109/L neutrophils (range)
ay to 20  109/L platelets (range)
eached 100% CDC in unseparated PB TNC
Median days (range)
eached 100% donor T cells in PB
Median days (range)
eached 100% donor granulocytes in PB
Median days (range)
ytogenetic remission after transplantation
Acute myelogenous leukemia/myelodysplasia
Chronic myeloid leukemia/other myeloid malignancies
eached undetectable bcr/abl (CML), median day (range)
MV infection (1-y CumInc)
cute GVHD (100-d CumInc; 95% CI)
Grade I
Grade II
Grade III
Grade IV
ay of onset of acute GVHD, median (range)
hronic GVHD (2 y)
Limited
Extensive
inal m-s GVHD (2-y CumInc; 95% CI)
onditioning-related organ toxicities
Grade 3/4 mucositis
Required parenteral nutrition
Days on parenteral nutrition
Hepatic veno-occlusive disease
Maximum serum total bilirubin, median, mol/L (range)
Day maximum bilirubin, median, mol/L (range)
Maximum serum AST, median, IU/L (range)
Day maximum AST, median IU/L (range)
Maximum serum ALT, median, IU/L (range)
Day maximum ALT, median, IU/L (range)
eceived DLI as specified per protocol
onrelapse mortality (2-y CumInc, 95% CI)
100-d nonrelapse mortality (% CumInc; 95% CI)
-y relapse incidence (% CumInc; 95% CI)
-y overall survival (% probability; 95% CI)
edian overall follow-up, d (range)
edian follow-up in survivors (range)
arentheses contain percentage, probability, or cumulative inciden
B indicates peripheral blood; GVHD, graft-versus-host disease;
chronic extensive GVHD); NS, nonsigniﬁcant and P  0.3; CD
myelogenous leukemia; CMV, cytomegalovirus; DLI, donor lym
AST, aspartate aminotransferase; ALT, alanine aminotransferas
One of the 16 cases of aGVHD in the Flu-TBu (targeted) group oc
(before DLI) acute GVHD was 20% (95% CI, 13%-32%) in th
(P  .70).
One patient achieved complete donor chimerism after a DLI.
P  .01 for earlier 100% donor chimerism in granulocytes than i
One case of cGVHD in each group (Flu-TBu and Flu-Bu) occurre
spontaneous cGVHD was 65% (95% CI, 49%-74%) in the targeteransplantation with active disease. There was a com- (
B & M Tlete cytogenetic response in 14 (74%) of 19 patients
ith AML/MDS who had an abnormal karyotype at
ransplantation and 10 of 11 patients with CML. In
he latter group of patients, the bcr/abl translocation
eached undetectable levels (b3a2/abl, 0.01  104)
n 8 of 9 evaluable patients at a median of day 210
geted Busulfan
Patients Nontargeted Patients P Value
4 (7-21) 16 (10-24) NS
2 (0-28) 11 (0-17) NS
31/32 (97) 26/28 (93)* NS
0 (17-150) 28 (21-170) NS
26/29 (90) 21/24 (88)* NS
5 (21-740)† 90 (21-248)† NS
29/29 (100) 22/24 (92)
0 (17-120)† 26 (21-248)† NS
10/13 (77) 4/6 (67) NS
6/6 (100) 5/6 (83)
5 (100) 3 (75) NS
0 (90-270) 330 (158-480)
4 (13) 1 (3) .06
6 (42; 30-54) 11 (35; 21-49) .4
6 4
4† 4† NS
4† 2† NS
2† 1† NS
0 (12-101) 38 (16-106) .3
24/26§ 20/27§ .3
14§ 6
10 14§
7 (45; 27-63) 17 (49; 29-69) NS
4 (13) 3 (10) NS
2 (6) 6 (21)
4 and 6 Median 10 (3-27) .001
0 1 (3), moderate
3 (16-43) 22 (9-115)
9 (14-60) 17 (8-49)
8 (30-78) 46 (15-176)
2 (5-60) 11 (0-60)
2 (42-180) 72 (22-217)
8 (6-60) 11 (0-60)
3 (9) 7 (23) .08
5 (12; 3.4-21.1) 7 (19; 9.3-32) NS
%; 0.1%-10.1% 3%; 0.1%-9.4% NS
7 (21; 8.2-39.4) 7 (20.7; 6.7-43.4) NS
1 (65; 47-81) 16 (53; 34-70) NS
9 (76-2161) 1394 (236-2349) NS
9 (300-2166) 1658 (395-2198) .10
HD, moderate-to-severe GVHD (grade II–IV acute GVHD or
plete donor chimerism; TNC, total nucleated cells; CML, chronic
e infusion; CumInc, cumulative incidence; CI, conﬁdence interval;
after DLI. The cumulative incidence of grades II to IV spontaneous
ted group and 22% (95% CI, 14%-34%) in the nontargeted group
lls.
DLI (limited and extensive cGVHD). The cumulative incidence of
and 61% (95% CI, 42%-70%) in the nontargeted group (P  .50).Tar
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4ere found between the Bu dose-targeted and non-
argeted groups.
isease Relapse
Seven patients (22%) in the Flu-TBu group and 7
23%) in the Flu-Bu group showed overt disease re-
apse after transplantation that occurred at a median
ime after transplantation of 174 days (range 49-670
ays) and 158 days (range, 30-429 days), respectively.
he 2-year incidence of relapse was 21% (95% CI,
.2%-39.2%) and 29% (95% CI, 8.7%-41.4%), re-
pectively (P  .60). In multivariate analysis, only not
eveloping cGVHD (HR, 10.8; 95% CI, 2.6-45.4;
 .001) had an independent effect on relapse: 9
atients relapsed (n  5) or died (n  4) before day
100, and 4 of 42 (incidence, 6%; 95% CI, 1.2%-
4%) evaluable patients with cGVHD and 6 of 11
incidence, 56%; 95% CI, 21%-78%) patients without
GVHD relapsed (P  .0001).
onor Lymphocyte Infusion
DLIs were given to 3 (9%) patients in the targeted
roup and 8 (27%) patients in the nontargeted group
P  .08), with prior AML-type chemotherapy in 2
ases from both groups. DLIs were used for overt
isease relapse in 6 cases and for an increase in MRD
ithout GVHD in 5 cases. Two of 6 patients with
vert relapse achieved CR after chemotherapy fol-
owed by aGVHD (1 died from infection, and 1 re-
ains in CR with cGVHD 12 months after DLI).
our of 5 patients with MRD at the time of DLI
eveloped cGVHD and achieved CR, and all 4 are
Days post-transplant 
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PB) T cells and granulocytes were 100% of donor origin (complete
onor chimerism; CDC) in the 54 evaluable patients. CDC in PB
as reached earlier in granulocytes (——) than in T cells (– – – ),
ithout differences between transplantation groups.live and disease free 180 to 1560 days after DLI. (
44Because GVHD developed de novo in 3 patients
fter DLI, the ﬁnal incidences of aGVHD grades II to
V and cGVHD (spontaneous and induced by DLI or
brupt discontinuation of cyclosporine) were a little
igher than the spontaneous incidences described pre-
iously: 21% (95% CI, 17%-33%) ﬁnal grade II to IV
GVHD and 70% (95% CI, 56%-84%) ﬁnal
GVHD, without any differences between study co-
orts.
urvival
Transplantation group had no effect on the 2-year
robabilities of OS and LFS; the 2-year OS was 65%
95% CI, 44%-77%) in the targeted group and 53%
95% CI, 34%-70%) in the nontargeted group (P 
40), whereas LFS was 61% (95% CI, 43%-78%) and
1% (95% CI, 32%-69%), respectively (P  .40). In
nivariate analysis, variables that decreased OS were
ge 60 years and older (70% versus 33%; P  .03),
eveloping aGVHD grades II to IV (64% versus 43%;
 .04), not developing cGVHD (77% versus 34%;
 .001), and low CD34 cell dose (6  106/kg;
7% versus 76%; P  .05). In multivariate analysis,
he only variables that decreased OS were not devel-
ping cGVHD (HR, 7.6; 95% CI, 2.4-23.6; P  .001)
nd developing aGVHD grades II to IV (HR, 2.7;
5% CI, 1.1-6.5; P  .02). With respect to LFS, the
ariables that decreased LFS were a low CD34 cell
ose (6  106/kg; 72% versus 45%; P  .04), not
eveloping cGVHD (74% versus 34%; P  .0001),
nd age 60 years and older (71% versus 39%; P .05);
here was a trend for patient CMV seropositivity (85%
ersus 43%; P .10). In multivariate analysis, the only
ariable that decreased LFS was not developing
GVHD (HR, 7.3; 95% CI, 3.2-28.4; P  .001).
  24    12 0 
20 
10 
   0 
40 
   30 
    6    18 
Months post-transplant
In
ci
de
nc
e 
of
 N
on
-r
el
ap
se
 m
or
ta
lit
y 
igure 2. Incidence of nonrelapse mortality (NRM) according to
ransplantation group. The 2-year NRM was 12% (95% conﬁdence
nterval, 3.4%-21.1%) in the targeted group (– · – · ) and 10%
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Fludarabine and Targeted Busulfan as Conditioning Therapy
BISCUSSION
We have shown that a combination of Flu and
educed-dose oral Bu without antilymphocyte anti-
odies can be used safely to condition patients with
yeloid malignancies for allogeneic PBSC transplan-
ation from HLA-identical related donors. All patients
chieved sustained engraftment, with immediate com-
lete donor myeloid engraftment in most patients but
ore delayed T-cell engraftment in many cases. The
ay 100 and 2-year NRM (4% and 15%, respectively)
as low, especially considering that all patients had 1
r more formal contraindications to conventional
onditioning. Although several other RIC regimens
or myeloid malignancies have been reported,
26,27,31-35,55-59] a direct comparison of outcomes
etween series is not appropriate because most pub-
ished data include heterogeneous patients and meth-
ds. In this respect, our study differs from most others
n that only 1 conditioning regimen, donor type, and
tem cell source was used in all cases, and the median
ollow-up of more than 3 years is one of the longest
ublished to date in this setting.
Busulfan TDM seems to improve the outcome in
atients conditioned with oral Bu at a total dose of
6 mg/kg, [12-16,39] but the effect of TDM with
ower doses of oral Bu is unknown. Our data show that
DM led to Bu dose modiﬁcations in more than 50%
f the patients but had little effect in all major vari-
bles analyzed. On the basis of the observed low ad-
erse effect spectrum and low NRM in our 2 patient
roups, it seems improbable that TDM-directed indi-
idualized Bu dosing will improve the outcome of our
lu-Bu RIC strategy. However, more precise dose
elivery may be of value to increase the LFS of pa-
ients at very high risk for disease recurrence or Bu-
elated severe toxicity [32]. Thus, targeted doses of Bu
ay be especially important in the future, as the pa-
ient and donor population change, with older and
ore debilitated patients and more mismatched do-
ors being used for RIC allografts in many centers
orldwide. The recent availability of intravenous Bu
educes the variability of Bu exposure due to erratic
ut absorption, thus affording more reproducibility
etween doses in a given patient [60,61]. However, the
nterpatient rate of clearance of the drug is not solved
ith this new formulation, [13,15] and, thus, the need
or TDM with the intravenous formulation may also
e beneﬁcial [62].
Despite not ﬁnding any effect of TDM and dose
djustment of oral Bu in this setting, we still encour-
ge the comparison of homogeneous Bu-containing
oral or intravenous formulations) RIC allografts with
nd without TDM, especially in patients with a very
igh risk of Bu-related toxicity (liver disease; prior
adiation to the lungs, liver, or both; renal failure; or
oncomitant use of drugs that interfere with Bu phar- 1
B & M Tacokinetics). In such patients, reducing any unneces-
ary toxicity, even if of small magnitude, may eventually
educe morbidity and conditioning-related NRM.
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